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In 2012, the Czech and European clinical guidelines for diagnosis and treatment of heart
failure have been issued. The main difference between them is that the European
guidelines include both acute and chronic heart failure while our national guidelines
contain only chronic heart failure.
They differ even in the deﬁnition of heart failure; the European guidelines do not
include natriuretic peptides among the diagnostic criteria and response to treatment as an
auxiliary criterion in cases of unclear diagnosis.
Regarding signs and symptoms of heart failure, both guidelines are similar in this part,
they only differ in their categorization. In diagnosis section, the guidelines vary in certain
echocardiographic parameters, particularly of diastolic dysfunction. Cut-off points for
natriuretic peptides in chronic heart failure are entirely new in the European guidelines.
For patients presenting in a non-acute way, the optimum cut-off point is 125 pg/mL for
NT-proBNP and 35 pg/mL for BNP.
Drug groups for treatment of heart failure are similar in both documents. The European
guidelines do not contain perindopril among ACE inhibitors and recommend 5 mg twice
daily as the target dose of ramipril while 10 mg once daily is recommended in the Czech
guidelines. The target dose of losartan is 100 mg once daily in the Czech guidelines and
150 mg in the European guidelines. Triamteren and amilorid are among recommended
diuretics in the European guidelines, but not in the Czech ones.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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In 2012, new Guidelines for diagnosis and treatment of heart
failure of the Czech Society of Cardiology (ČKS) and the
European Society of Cardiology (ESC) have been issued [1–4].
Our Czech guidelines are coming out as the last national
Guidelines of the Czech Society of Cardiology since the ČKS
Committee agreed in summer 2011 that we would take over
European guidelines with our speciﬁc annotations, and we
would not create our national guidelines in the future. The
Czech guidelines were accepted for press at the end of 2011
but were published in journals Cor et Vasa and Internal
Medicine in spring 2012 and published in May 2012. The
European guidelines were presented and published also in
summer 2012. Thus, it is apparent that the authors of both
guidelines used similar knowledge and data when writing
these guidelines. However, interpretation of available data
can differ among authors. In what these guidelines differ? Obviously, the European guidelines concern both acute
and chronic heart failure while the Czech ones only
chronic heart failure. However, this difference is beyond
the scope of this paper. The Czech guidelines have 20 pages, 80 references, and 10
authors; the European guidelines have 60 pages, 270
references, and 24 authors. The ESC guidelines have a different structure than the Czech
guidelines. They usually comprise of very concise and very
general recommendations, which are followed with concise
“Key evidence” from clinical trials listed in points. Recom-
mendations and their classes and levels of evidence are
listed in individual tables; frequently one table contains
several groups of drugs or treatment modalities.
From the clinical point of view, both guidelines differ in
these substantial points.2. Definition of heart failure
In the European guidelines, we can ﬁnd the deﬁnition of
systolic and diastolic heart failure (Table 1); in the original,
also in Table 1.
The diagnostic criteria for heart failure according to the
Czech guidelines are listed in Table 2.
Table 2 – Diagnostic criteria for heart failure.
Diagnostic criteria for heart failure
1. Symptoms typical of heart failure (dyspnea at rest or on exertion, fatigue, tiredness)
2. Signs typical of heart failure (tachycardia, tachypnoea, gallop rhythm, pulmonary crepitations, pleural effusion, elevated jugular
venous pressure, peripheral edema, hepatomegaly, cardiomegaly, third heart sound, murmur)
3. Evidence of disturbed cardiac function at rest (documented systolic or diastolic dysfunction at echocardiography or other imaging,
elevated natriuretic peptides)
4. Response to treatment (in case the diagnosis is unclear)
Table 1 – Diagnosis of heart failure.
The diagnosis of HF-REF requires three conditions to be satisfied:
1. Symptoms typical of HF
2. Signs typical of HFa
3. Reduced LVEF
The diagnosis of HF-PEF requires four conditions to be satisfied:
1. Symptoms typical of HF
2. Signs typical of HFa
3. Normal or only mildly reduced LVEF and LV not dilated
4. Relevant structural heart disease (LV hypertrophy/LA enlargement) and/or diastolic dysfunction
HF—Heart failure; HF-PEF—heart failure with ‘preserved’ ejection fraction; HF-REF—heart failure and a reduced ejection fraction;
LA—left atrial; LV—left ventricular; LVEF—left ventricular ejection fraction.
a Signs may not be present in the early stages of HF (especially in HF-PEF) and in patients treated with diuretics.
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do not include natriuretic peptides among the diagnostic
criteria as well as response to treatment as an auxiliary
criterion in cases of unclear diagnosis.3. Differences in diagnosis
3.1. Symptoms and signs
There are no signiﬁcant differences; only the table in the ESC
document is divided in typical and less typical symptoms and
speciﬁc and less speciﬁc signs (see Table 3, in original
Table 4). On the contrary, the text part is more detailed in
the Czech guidelines (Table 4).3.2. ECG and chest X-ray
The European guidelines present quite extensive table with
various ECG abnormalities and associated clinical conditions
that can cause them. Let us mention some of them: supra-
ventricular tachycardia and bradycardia, ventricular prema-
ture beats, Q waves, low QRS voltage, left ventricular (LV)
hypertrophy, atrioventricular block, wide QRS complex, or left
bundle brunch block. The Czech guidelines are more concise
in this section. It is only stated that ECG can show practically
any changes, and that normal ECG is unlikely but does not
exclude heart failure.
Regarding chest X-ray, the Czech guidelines are more
comprehensive. They describe a four-step scale of pulmonary
congestion (the European guidelines do not mention any) andan upper limit of cardiothoracic index 0.5 (cardiothoracic
index is not mentioned in the European guidelines).
3.3. Natriuretic peptides
According to the Czech and European guidelines, assessment
of plasma levels of natriuretic peptides and their fragments,
particularly BNP a NT-proBNP, plays an important role in
heart failure diagnosis.
Exclusion cut off points differ slightly. In the European
guidelines, exclusion thresholds for patients with acute onset
of dyspnea are 300 pg/mL for NT-proBNP and 100 pg/mL for BNP.
For patients presenting in a non-acute way, the exclusion cut off
points are 125 pg/mL for NT-proBNP and 35 pg/mL for BNP.
By contrast, the Czech guidelines suggest slightly different
values. The exclusion points that exclude heart failure in an
untreated patient are o100 pg/mL for BNP and o400 pg/ml
for NT-proBNP. In treated patients, normal levels of BNP or
NT-proBNP do not exclude heart failure.
In acute heart failure setting (including decompensated
chronic heart failure), BNP 4400 pg/mL or NT-proBNP
42000 pg/mL is clearly the pathological value. The values
between 100 and 400 pg/mL for BNP and 400 and 2000 pg/mL
for NT-proBNP are considered as a gray zone.
3.4. Echocardiography
The Czech and European guidelines for diagnosis and treat-
ment of heart failure 2012 both agree on the point that
echocardiography belongs among essential diagnostic meth-
ods in the diagnosis of heart failure since it proves and
quantiﬁes impaired systolic and diastolic LV function. Both
Table 4 – Symptoms and signs according to the CˇKS.
Pulmonary Cardiac Systemic
Signs Crepitations Tachycardia Weight gain
Pleural effusion Third or fourth heart sound Peripheral edema
Tachypnoea Cardiomegaly Jugular venous distension
LV hypertrophy Hepatomegaly
Irregular pulse Hepatojugular reflux
Soft pulse Cyanosis
Ascites
Symptoms Dyspnea Palpitations Fatigue
Ortopnoea Chest pain Tiredness
Cough Diaphoresis
Cardiac asthma Nocturia
Oliguria
Insomnia
Nausea
Vomiting
Obstipation
LV—Left ventricular.
Table 3 – Symptoms and signs according to the ESC.
Symptoms Signs
Typical More specific
Breathlessness Elevated jugular venous pressure
Orthopnoea Hepatojugular reflux
Paroxysmal nocturnal dyspnea Third heart sound (gallop rhythm)
Reduced exercise tolerance Laterally displaced apical impulse
Fatigue, tiredness, increased time to recover after exercise Cardiac murmur
Ankle swelling
Less typical Less specific
Nocturnal cough Peripheral edema (ankle, sacral, scrotal)
Wheezing Pulmonary crepitations
Weight gain (42 kg/week) Reduced air entry and dullness to percussion at lung bases (pleural effusion)
Weight loss (in advanced heart failure) Tachycardia
Bloated feeling Irregular pulse
Loss of appetite Tachypnoea (416 breaths/min)
Confusion (especially in the elderly) Hepatomegaly
Depression Ascites
Palpitations Tissue wasting (cachexia)
Syncope
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ejection fraction (EF) has a fundamental role in the diagnosis
of heart failure. If LVEF is reduced, we use the term heart
failure with reduced EF (HF-REF). The importance of other
parameters of LV systolic function for the diagnosis of HF-REF
is still a subject of intense research.
The European and Czech guidelines both also emphasize
the principle role of echocardiography in the diagnosis of heart
failure with preserved EF (HF-PEF). This diagnosis is quite
difﬁcult to make, and diagnostic criteria still evolve. Therefore,
it is not surprising that every new guideline for assessment
of diastolic function, which is necessary for the diagnosis of
HF-PEF, is slightly different in comparison to the older one.
The Czech guidelines are based on the text published in 2007
by Paulus et al. [5]. According to these recommendations, con-
ﬁrmation of diastolic dysfunction is an inherent part of dia-
gnosis of HF-PEF. Non-invasive echocardiographic diagnosis ofdiastolic dysfunction is based particularly on parameters
obtained by pulsed wave Doppler analysis of mitral inﬂow
and pulmonary vein ﬂow and tissue Doppler analysis of mitral
annular velocity. The measured parameters are peak early (E)
and peak atrial (A) mitral inﬂow velocity, deceleration time of
early mitral inﬂow velocity (DT), peak early diastolic velocity of
mitral annulus (Ea), and difference in the duration of pulmon-
ary venous (Ard) and mitral (Ad) ﬂow at atrial contraction Ard–
Ad. According to the Czech guidelines, clinical signs of heart
failure together with good systolic function (EF450%) of
nondilated LV and documented impaired LV relaxation, ﬁlling,
diastolic distensibility, and diastolic stiffness (i.e., documented
diastolic dysfunction) prove HF-PEF. An important parameter
representing diastolic dysfunction with increased ﬁlling pres-
sure of LV is E/Ea ratio 415, which with signs of heart failure,
normal EF, and nondilated LV are indicative of HF-PEF ([1],
Table 9, page 1803). If E/Ea is borderline (154E/Ea48), HF-PEF
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tides (NT-proBNP 4220 pg/mL or BNP 4200 pg/mL) or by the
presence of at least one of following parameters: E/Ao0.5 in
combination with DT4280ms in patients older than 50 years,
Ard–Ad430ms, LAVi (left atrial volume index)440mL/m2, LV
mass index 4122 g/m2 in women or 4149 g/m2 in men, or
atrial ﬁbrillation. If natriuretic peptides are increased, HF-PEF
can be conﬁrmed by one of following ﬁndings: E/Ea48, E/Ao0.5
in combination with DT4280ms in patients over 50 years, Ard–
Ad 430ms, LAVi440mL/m2, LV mass index 4122 g/m2 in
women or 4149 g/m2 in men, or atrial ﬁbr-illation.
The new European guidelines contain slightly modiﬁed
diagnosis of diastolic dysfunction in the HF-PEF diagnosis
section. The term “diastolic dysfunction” is substituted with
a more precise description “relevant structural heart disease
and/or diastolic dysfunction” (structural heart disease com-
prises LV hypertrophy and left atrial enlargement). This
difference is not signiﬁcant since importance of LAVi and LV
mass is emphasized in the Czech guidelines as well. The
European guidelines present these echocardiographic para-
meters for diagnosis of diastolic dysfunction (1): decreased Ea
(this parameter is newly termed e′) at the septal annulus
o8 cm/s, at the lateral annulus o10 cm/s, or their average
o9 cm/s; E/Ea415 (if E/Ea is 8–15, it is necessary to evaluate
other parameters), and Ard–Ad430 ms. The guidelines recom-
mend measurements of mitral inﬂow E/A ratio without deﬁn-
ing requisite values for diastolic dysfunction diagnosis and
also newly recommend to measure E/A ratio during the
Valsalva maneuver to differentiate the “pseudonormal” ﬁlling
pattern in patients with E/A ratio of 1–2. Natriuretic peptides
are not mentioned in the diagnosis of diagnostic dysfunction
section in the European guidelines, which is probably the main
difference. It is stated in the guidelines that no single echo-
cardiographic parameter is sufﬁciently accurate to be used in
isolation for the diagnosis of diastolic dysfunction, and the
presence of at least 2 abnormal measurements and/or atrial
ﬁbrillation increases likelihood of diastolic dysfunction. Never-
theless, the Czech guidelines also recommend combination of
more echocardiographic parameters and conﬁrmation or
exclusion of atrial ﬁbrillation. It may be summarized that
there is an agreement between the Czech and European
guidelines in the principal points of diastolic dysfunction
diagnosis within the frame of HF-PEF diagnosis. Minor and
less clinically important differences can be found in para-
meters selection for diastolic dysfunction assessment. The
Czech guidelines stress also the role of natriuretic peptides,
but the echocardiography examination remains to be crucial.
On the opposite the role of other biochemical examination is
more preciously mentioned in the European guidelines.4. Treatment differences
Lifestyle changes are not mentioned as a part of heart failure
treatment in the European guidelines. They are listed at the end
of the document (Table 27 in the original) among topics that
should be discussed with patients and are part of patient's
education. Similarly with the Czech guidelines, it is recom-
mended to quit smoking, only modest intake of alcohol, salt
restriction in NYHA III–IV patients, and ﬂuid restriction inpatients who tend to retain ﬂuids. Traveling is permitted, but it
is advised to carry a written report of medical history with
current medication regimen and carry extra medication in case
of complications. Patients using amiodarone should not stay
longer in the sun. Regular exercise according to patient's
physician is fully recommended. Recommendations for sexual
activity are similar. It is stated in the chapter 11.10 that in
patients with erectile dysfunction, phosphodiesterase V inhibi-
tors are not contraindicated other than in patients taking
nitrates. The European guidelines recommend inﬂuenza vaccine
in compliance with local guidelines and practice; the Czech
guidelines in accordance with the American guidelines recom-
mend vaccination.
4.1. Heart failure prevention
Prevention of heart failure is discussed at the beginning of
Chronic heart failure treatment chapter in the ČKS guidelines.
Primary and secondary prevention is deﬁned herein. Recom-
mendations for secondary prevention are classiﬁed I, A.
Surprisingly, prevention is not mentioned in the ESC
guidelines.
4.2. ACE inhibitors
ACE inhibitors (ACEI) are one of the most important drug
groups in the treatment of heart failure. Class of recommen-
dations is similar for ACEI in both the guidelines. The major
difference is that in the European guidelines, perindopril is not
included among recommended ACEI while in the Czech ones,
perindopril is recommended, and doses for both salts are
advised. The authors of the European guidelines justify this
fact by the lack of mortality data for perindopril in heart failure
patients although the non-mortality data from PREAMI study
and also PEP CHF study in patients with diastolic heart failure or
data of heart failure patients from EUROPA trial fully support
perindopril administration in patient with this condition.
Recommended daily dose for ramipril is 5 mg twice daily
in the European guidelines and 10 mg once daily in the
Czech ones.
4.3. Angiotensin receptor blockers
The maximum recommended dose for losartan is 100 mg in
the Czech guidelines and 150 mg in the European ones.
The Czech guidelines recommend using combination of
ACEI and angiotensin receptor blocker (ARB) in case of hyper-
tension with proteinuria (class of recommendation IIa, level of
evidence B). This is not mentioned in the ESC guidelines.
On the contrary, the European guidelines recommend com-
bination of ACEI+ARB together with beta-blockers (BB) in case
of intolerance to aldosterone receptor antagonists to decrease
risk of hospitalization for heart failure (class of recommenda-
tion I, level of evidence A).
4.4. Beta-blockers
In the ESC guidelines, there is a table with detailed description
of BB usage (similarly to other drug groups) where is speciﬁed:
Why? Who and when? Which BB and what dose? How to use
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mention additional BB studies as BEST with bucindolol, which,
however, did not meet the primary endpoint, and COMET trial
comparing carvedilol with short-acting metoprolol. The ESC
guidelines emphasize that BB administration should continue
even in periods of decompensation with reduced dose. BB
should be temporarily discontinued only in patients with
shock or severe hypoperfusion and started again as soon as
possible.4.5. Digoxin
This section is more detailed in the ČKS guidelines including
description of digitalis toxicity and its treatment and recom-
mended digoxin serum concentrations (0.6–1.2 ng/mL). These
details are not included in the ESC guidelines.
Both guidelines differ slightly (not signiﬁcantly) in classes
or recommendations and levels of evidence in particular
clinical situations (Table 5).4.6. Diuretics
There are great differences in the diuretics section. The ESC
guidelines again contain a detailed table similarly as for BB
showing how to use diuretics. In the ESC guidelines, diuretics
that are not registered in Czech Republic are listed in a table as
well as potassium-sparing diuretics triamterene and amilor-
ide. The guidelines also discuss how to use potassium-sparing
diuretics together with ACEI/ARB. It is emphasized that com-
bination ACEI+ARB+mineralocorticoid receptor antagonist is
not recommended.4.7. Mineralocorticoid receptor antagonists
Mineralocorticoid receptor antagonists again have a detailed
table why, how, when and who should use them. There is only
slight difference in dosage (Tables 6 and 7).Table 5 – Level of reccomendation for digoxin use.
Clinical situation CKS guidelines
Systolic heart failure+atrial fibrillation with
rapid ventricular rate
I C
Systolic heart failure+sinus rhythm:
(a) if BB is not tolerated Absent
(b) if symptomatic with standard treatment
(including BB)
IIa B (if clinically effe
discontinue)
Diastolic heart failure (HF-PEF) IIb B
Table 6 – Dosage of mineralocorticoid receptor antagonists ac
Generic drug Initial dose (mg
Spironolactone 12.5–25 mg
Eplerenone 25 mg4.8. If channel blockers
Ivabradine is recommended in patients with heart failure, sinus
rhythm, and heart rate ≥70 bpm despite maximum tolerated
dose of beta-blockers. The Czech guidelines recommend ivab-
radine in this indication in class of recommendation I while the
ESC guidelines in IIa. Moreover, ESC guidelines contain indica-
tion for ivabradine in patients with beta-blocker intolerance
(class IIb, level of evidence C) while the Czech guidelines do not
mention this indication.
4.9. Antiplatelet and anticoagulant therapy
Recommendations for antiplatelet and anticoagulant therapy
are described in detail in the ČKS guidelines while in the ESC
guidelines, recommendations for anticoagulation are men-
tioned only in the atrial ﬁbrillation section, and for patients
with heart failure without atrial ﬁbrillation, anticoagulant
therapy is not recommended. In patients with atrial ﬁbrilla-
tion, it is recommended to use CHA2DS2-VASC and HAS BLED
score according to the ESC guidelines for atrial ﬁbrillation
from 2010. Regarding new anticoagulants, there are men-
tioned only thrombin inhibitors and oral factor Xa inhibitors
with a note that their use is contraindicated in patients with
creatinine clearance o30 mL/min, and serial monitoring of
renal function is required.
4.10. Hypolipidemic treatment
There are no signiﬁcant differences. In the ČKS guidelines,
statins are recommended in class of recommendations IIb with
level of evidence B. In the ESC guidelines, statins are included in
the section “Treatments not recommended (unproven beneﬁt)”.
4.11. Other treatments
The ESC guidelines also mention hydralazine, isosorbide dini-
trate and omega-3 polyunsaturated fatty acids. Use of these
drugs is not supported by signiﬁcant evidence data. The Czech
guidelines do not mention these drugs.ESC guidelines
I B (the second drug if BB is not effective in
controlling ventricular rate)
IIb B
ctive; if not, IIb B
Absent
cording to the CˇKS.
) Maximum daily dose (mg)
25–50 mg
25–50 mg
Table 8 – Patients in whom palliative care should be considered.
Frequent admission to hospital or other serious episodes of decompensation despite optimized treatment
Heart transplantation and mechanical circulatory support ruled out
Chronic poor quality of life with NYHA class IV symptoms
Cardiac cachexia/low serum albumin
Dependence in most activities of daily living
Clinically judged to be close to the end of life
Table 9 – Key components of palliative care service.
Frequent assessment of patient’s physical, psychological, and spiritual needs
Focus on complete symptom relief from both HF and other co-morbidities
Advanced care planning, taking account of preferences for place of death and resuscitation (which may include deactivating ICD)
Table 7 – Recommended doses according to the ESC.
Recommended doses of major drug groups according to the ESC guidelines
Initial dose Target dose
ACE inhibitors
Captopril 3 6.25 mg 350 mg
Enalapril 2 2.5 mg 210–20 mg
Lisinopril 1 2.5−5.0 mg 120–35 mg
Ramipril 1 2.5 mg 25 mg
Trandolapril 1 0.5 mg 14 mg
Beta-blockers
Bisoprolol 1 1.25 mg 110 mg
Carvedilol 2 3.125 mg 225–50 mg
Metoprolol succinate (CR/XL) 1 12.5–25 mg 1200 mg
Nebivolol 1 1.25 mg 110 mg
Angiotensin receptor blockers
Candesartan 1 4–8 mg 132 mg
Valsartan 2 40 mg 2160 mg
Losartan 1 50 mg 1150 mg
Mineralocorticoid receptor antagonists
Spironolactone 1 25 mg 125–50 mg
Eplerenone 1 25 mg 150 mg
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 0 1 – e 3 0 8 e307Recommended doses are shown in Table 7 (in original
Table 14) in the ESC guidelines.
4.12. Guidelines for pharmacologic treatment of diastolic
heart failure (HF-PEF)
There are no signiﬁcant differences. The Czech guidelines
present more speciﬁc but still general and empiric recommen-
dations, which have class of recommendations IIa and level of
evidence C. The ESC guidelines contain very general recom-
mendations without classiﬁcation.
4.13. Elimination methods
More detailed recommendations regarding the use of elimina-
tion methods in heart failure are in the ČKS guidelines. Only
one sentence in the ESC guidelines mentions that veno-venous ultraﬁltration (VVUF) can be used in patients that do
not respond to diuretics.
4.14. Palliative care
The ČKS guidelines describe brieﬂy feasible practice in patients
with end-stage heart failure. The ESC guidelines pay more
attention to this terminal phase of the disease. Recommenda-
tions are listed in Tables 8 and 9 (in original Tables 28 and 29).
The ESC guidelines suggest considering deactivating ICD,
which is not permitted by Czech legislation!
4.15. Treatment of heart failure guided by natriuretic
peptides measurements
There are no signiﬁcant differences. The ČKS guidelines
describe this practice as “controversial” and give it
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 0 1 – e 3 0 8e308classiﬁcation IIb, B. The same information is in the ESC
guidelines but without classiﬁcation.
4.16. Cardiac resynchronization therapy
Comparison of recommendations for cardiac resynchroniza-
tion therapy in patients with heart failure will be the subject
of a separate article.
4.17. Coronary revascularization
The European guidelines classify patients in subgroups: Left main stenosis+angina pectoris+expected
survival 41 year, recommendation I, C. Angina pectoris+two or three-vessel coronary disease
(with LAD)+expected survival 41 year, recommendation
I, B (evidence—STICH study).
Percutaneous coronary intervention may be considered as
an alternative to surgery, but evidence is weak (IIb, C).
Revascularization is not recommended in patients without
angina pectoris and viable myocardium (III, C). The condition
of angina pectoris for revascularization indication is dispu-
table since in some patients, ischemia may not be presented
as angina pectoris but its equivalents.
4.18. Aneurysmectomy
According to the Czech guidelines, endoventricular plasty
may be considered as a supplement to surgical coronary
revascularization in patients with symptomatic left ventricu-
lar aneurysm (IIb, B).
In the European guidelines, LV reconstruction is not
recommended for routine use and is discussed further in
the revascularization guidelines.
4.19. Mitral valve repair
In the Czech guidelines, mitral valve plasty as a supplement
to coronary revascularization is recommended in patients
with severe mitral regurgitation (I, C) and in patients with
non-ischemic cardiomyopathy as a possible part of care (IIa,
C). The option of valve replacement is also mentioned, as well
as indications for atrial ablation and left atrial appendage
closure in patients with atrial ﬁbrillation. According to the
ESC guidelines, the role of valve surgery in patients with non-
ischemic functional mitral regurgitation is questionable
(similarly in the ČKS guidelines).
In patients with high surgical risk edge-to-edge repair may
be considered. The ESC guidelines do not assign a class of
recommendations to any of mitral valve procedures.
4.20. Aortic valve replacement
Aortic valve replacement is recommended in patients with
severe aortic stenosis and selected patients with severe aortic
regurgitation in the ČKS guidelines (I, C). In the ESC guidelines,surgery is recommended in patients with mean aortic gradient
440mmHg regardless of LV ejection fraction. In patients with
mean gradient o40mmHg and ejection fraction o40%, dobu-
tamin stress echocardiography is recommended.
Classes of recommendations are not assigned in the ESC
document.
4.21. Heart transplantation
There are no signiﬁcant differences. The ČKS guidelines
specify indications more in detail, and contraindications are
classiﬁed as absolute, relative, and temporary. Information in
the ČKS document is more detailed including survival data.
Class of recommendations is I and level of evidence C in
the Czech guidelines; it is not assigned in the ESC document.
4.22. Mechanical circulatory support
The Czech guidelines contain particular information on
mechanical circulatory support (MCS) as bridge to heart
transplantation. This is the most common indication for
long-term MCS in our country. Indications and contraindica-
tions of LV assist device are listed in a table.
Class of recommendations I, level of evidence A (as bridge
to transplantation).
In the European guidelines, also other indications for MCS
are listed in a table (bridge to decision, bridge to recovery, and
destination therapy). MCS as a destination therapy is still not
accepted by insurance companies in Czech Republic.
MCS as bridge to transplantation has classiﬁcation I, A in
the ČKS guidelines and I, B in the ESC ones. MSC as a
destination therapy in selected patients who are not adept
for heart transplantations (predicted survival 41 year with
good quality of life) has classiﬁcation IIa, B in the ESC
guidelines.
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